PMID- 28367855
OWN - NLM
STAT- MEDLINE
DCOM- 20171212
LR  - 20171212
IS  - 2186-1005 (Electronic)
IS  - 1341-1098 (Linking)
VI  - 23
IP  - 3
DP  - 2017 Jun 20
TI  - Early Antithrombotic Therapy after Bioprosthetic Aortic Valve Replacement in
      Elderly Patients: A Single-Center Experience.
PG  - 128-134
LID - 10.5761/atcs.oa.16-00297 [doi]
AB  - PURPOSE: Early antithrombotic therapy after bioprosthetic aortic valve
      replacement (AVR) is controversial. This study aimed to retrospectively compare
      between warfarin and aspirin treatment in the 3 months after bioprosthetic AVR
      for elderly patients more than 60 years old, and to determine the optimal
      antithrombotic therapy. METHODS: This retrospective study included 479 patients
      in single center from January 1994 to June 2014. Patients were divided into two
      groups (Wa group, warfarin; As group, aspirin). We searched our computerized
      clinical database for thromboembolic or bleeding events. Propensity score
      analysis was conducted to adjust for selection bias. RESULTS: All patients,
      except one patient, were followed-up in the out-patient department for 3 months
      after the operation. In all, 86 propensity-matched patient-pairs were derived.
      Early operative outcomes were similar in both the groups. There are one patient
      of thromboembolic event and three patients of bleeding events, but the prevalence
      was not significantly different (p >0.999). CONCLUSION: The incidence of
      thromboembolic and bleeding events during early 3 months after bioprosthetic AVR 
      were similar in Wa and As groups. If the patient does not have indications of
      warfarin, early antithrombotic therapy with aspirin only may be easier and more
      feasible for elderly patients.
FAU - Lee, Seok In
AU  - Lee SI
AD  - Department of Thoracic and Cardiovascular Surgery, Gil Medical Center, Gachon
      University, Incheon, Korea.
FAU - Lee, Kyo Seon
AU  - Lee KS
AD  - Department of Thoracic and Cardiovascular Surgery, Chonnam National University
      Hospital, College of Medicine, Gwangju, Korea.
FAU - Kim, Joon Bum
AU  - Kim JB
AD  - Department of Thoracic and Cardiovascular Surgery, Asan Medical Center,
      University of Ulsan College of Medicine, Seoul, Korea.
FAU - Choo, Suk Jung
AU  - Choo SJ
AD  - Department of Thoracic and Cardiovascular Surgery, Asan Medical Center,
      University of Ulsan College of Medicine, Seoul, Korea.
FAU - Chung, Cheol Hyun
AU  - Chung CH
AD  - Department of Thoracic and Cardiovascular Surgery, Asan Medical Center,
      University of Ulsan College of Medicine, Seoul, Korea.
FAU - Lee, Jae Won
AU  - Lee JW
AD  - Department of Thoracic and Cardiovascular Surgery, Asan Medical Center,
      University of Ulsan College of Medicine, Seoul, Korea.
FAU - Jung, Sung-Ho
AU  - Jung SH
AD  - Department of Thoracic and Cardiovascular Surgery, Asan Medical Center,
      University of Ulsan College of Medicine, Seoul, Korea.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Observational Study
DEP - 20170329
PL  - Japan
TA  - Ann Thorac Cardiovasc Surg
JT  - Annals of thoracic and cardiovascular surgery : official journal of the
      Association of Thoracic and Cardiovascular Surgeons of Asia
JID - 9703158
RN  - 0 (Fibrinolytic Agents)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aortic Valve/physiopathology/*surgery
MH  - Aortic Valve Insufficiency/diagnosis/physiopathology/*surgery
MH  - Aortic Valve Stenosis/diagnosis/physiopathology/*surgery
MH  - Aspirin/*administration & dosage/adverse effects
MH  - *Bioprosthesis
MH  - Chi-Square Distribution
MH  - Drug Administration Schedule
MH  - Female
MH  - Fibrinolytic Agents/*administration & dosage/adverse effects
MH  - *Heart Valve Prosthesis
MH  - Heart Valve Prosthesis Implantation/adverse effects/*instrumentation
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Propensity Score
MH  - Prosthesis Design
MH  - Republic of Korea
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Thromboembolism/etiology/prevention & control
MH  - Time Factors
MH  - Treatment Outcome
MH  - Warfarin/*administration & dosage/adverse effects
PMC - PMC5483859
OTO - NOTNLM
OT  - aortic valve replacement
OT  - bioprostheses
OT  - oral anticoagulation
EDAT- 2017/04/04 06:00
MHDA- 2017/12/13 06:00
CRDT- 2017/04/04 06:00
PHST- 2017/04/04 06:00 [pubmed]
PHST- 2017/12/13 06:00 [medline]
PHST- 2017/04/04 06:00 [entrez]
AID - 10.5761/atcs.oa.16-00297 [doi]
PST - ppublish
SO  - Ann Thorac Cardiovasc Surg. 2017 Jun 20;23(3):128-134. doi:
      10.5761/atcs.oa.16-00297. Epub 2017 Mar 29.